MedMesh.i
Checkpoint
PubMed
Racine
Checkpoint
PubMed
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (PubMed)

Index « MedMesh.i » - entrée « Hepcidins »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Hepatomegaly < Hepcidins < Hereditary Autoinflammatory Diseases  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 8.
Ident.Authors (with country if any)Title
001216 (2014) E A Galushko[The clinical significance of hepcidin detection in the patients with anemia and rheumatoid arthritis].
001589 (2013) John D. Isaacs ; Olivier Harari ; Uwe Kobold ; Janet S. Lee ; Corrado BernasconiEffect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis.
001606 (2013) Soken-Nakazawa J. Song ; Mitsuhiro Iwahashi ; Naohisa Tomosugi ; Kazuko Uno ; Jiro Yamana ; Seizou Yamana ; Tomoyasu Isobe ; Hiroki Ito ; Hiroshi Kawabata ; Kazuyuki YoshizakiComparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients.
001690 (2012) Brady Lee Stein [États-Unis]The anemia of inflammation.
001977 (2010) Misato Hashizume [Japon] ; Yasushi Uchiyama ; Naoto Horai ; Naohisa Tomosugi ; Masahiko MiharaTocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production.
001A38 (2010) Soken-Nakazawa J. Song [Japon] ; Naohisa Tomosugi ; Hiroshi Kawabata ; Takayuki Ishikawa ; Teppei Nishikawa ; Kazuyuki YoshizakiDown-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.
001C00 (2007) Hiroshi Kawabata ; Naohisa Tomosugi ; Junya Kanda ; Yasuhiro Tanaka ; Kazuyuki Yoshizaki ; Takashi UchiyamaAnti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
001C95 (????) Satoshi Suzuki [Japon] ; Souichiro Nakano [Japon] ; Seiichiro Ando [Japon] ; Ran Matsudaira [Japon] ; Yoshinori Kanai [Japon] ; Kenjiro Yamanaka [Japon] ; Yoshinari Takasaki [Japon]Hepcidin-25 gives an indication of the therapeutic effectiveness of tocilizumab in rheumatoid arthritis - Relationship between disease activity of rheumatoid arthritis and anemia.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i -k "Hepcidins" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/MedMesh.i  \
                -Sk "Hepcidins" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Hepcidins
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021